Cited by 683Histone Deacetylase Inhibitors ResearchAdvanced Proteomics Techniques and ApplicationsMass Spectrometry Techniques and Applications

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

Bantscheff, Marcus, Hopf, Carsten, Savitski, Mikhail M, Dittmann, Antje, Grandi, Paola, Michon, Anne-Marie, Schlegl, Judith, Abraham, Yann, Becher, Isabelle, Bergamini, Giovanna, Boesche, Markus, Delling, Manja, Dümpelfeld, Birgit, Eberhard, Dirk, Huthmacher, Carola, Mathieson, Toby, Poeckel, Daniel, Reader, Valérie, Strunk, Katja, Sweetman, Gavain, Kruse, Ulrich, Neubauer, Gitte, Ramsden, Nigel G, Drewes, Gerard·2011·Nature Biotechnology

DOI 10.1038/nbt.1759

Open this paper in CoChat — free account

Abstract

The development of selective histone deacetylase (HDAC) inhibitors with anti-cancer and anti-inflammatory properties remains challenging in large part owing to the difficulty of probing the interaction of small molecules with megadalton protein complexes. A combination of affinity capture and quantitative mass spectrometry revealed the selectivity with which 16 HDAC inhibitors target multiple HDAC complexes scaffolded by ELM-SANT domain subunits, including a novel mitotic deacetylase complex (MiDAC). Inhibitors clustered according to their target profiles with stronger binding of aminobenzamides to the HDAC NCoR complex than to the HDAC Sin3 complex. We identified several non-HDAC targets for hydroxamate inhibitors. HDAC inhibitors with distinct profiles have correspondingly different effects on downstream targets. We also identified the anti-inflammatory drug bufexamac as a class IIb (HDAC6, HDAC10) HDAC inhibitor. Our approach enables the discovery of novel targets and inhibitors and suggests that the selectivity of HDAC inhibitors should be evaluated in the context of HDAC complexes and not purified catalytic subunits.

Integrity signals

Registry

Crossref · 10.1038/nbt.1759

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Proteome survey reveals modularity of the yeast cell machinery
Gavin, A., Aloy, P., Grandi, P., Krause, R., Böesche, M., Marzioch, M., Rau, C., Jensen, L. J., Bastuck, S., Dümpelfeld, B., et al. (2006) · Nature · doi:10.1038/nature04532 · Cited by 2,570
Self-citation
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,456
Regulation of cellular metabolism by protein lysine acetylation
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010) · Science · doi:10.1126/science.1179689 · Cited by 1,910
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap
Olsen, J. V., de Godoy, L. M. F., Li, G., Maček, B., Mortensen, P., Pesch, R., Makarov, A., Lange, O., Horning, S. R., & Mann, M. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500030-mcp200 · Cited by 1,539
Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
The Cell as a Collection of Protein Machines: Preparing the Next Generation of Molecular Biologists
Alberts, B. (1998) · Cell · doi:10.1016/s0092-8674(00)80922-8 · Cited by 1,411

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 601–683 of 683

Development and Evaluation of Chemical Probes for the Study of Histone Demethylases
Marholz, L. J. (2015) · CU Scholar (University of Colorado Boulder)
Role of endogenous retrovirus promoter activity in tumor suppression
Krönung, S. K. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5097
Stress management : multilayer regulation of the heat shock response
Budzyński, M. A. (2017) · Doria (University of Helsinki) · doi:10.13140/rg.2.2.16736.48641
HDACi-induced DNA damage: identifying potential endpoints for safety assessment
Wang, W. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Targeting lysine acetylation in inflammatory lung diseases
van den Bosch, T. (2017) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs
Tudy, P. S. (2014)
Analysis of the physiological role of histone deacetylase 3 (HDAC3) and its regulation by inositol phosphates
Wright, L. C. (2017) · Figshare
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials
Patel, M. R., Patel, S. P., & Kurzrock, R. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_9
The Epigenetics of Autoimmunity and Epigenetic Drug Discovery
Tough, D. F., Rioja, I., Tak, P. P., & Prinjha, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00015-5
Mass Spectrometry and Chemical Biology in Epigenetics Drug Discovery
Feller, C., Weigt, D., & Hopf, C. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch4
Self-citation
Two-dimensional electrophoresis protein profiles of HL-60 and CCRF-CEM cell lines treated with epigenetic modification drugs
Aziee, S., Yassim, H. M., Yusoff, S. M., Shamsuddin, S., Wahab, R. A., & Johan, M. F. (2019) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2019.027.3.02
Evolutionary, structural and functional features of cellular signalling networks
Lang, B. (2012) · Apollo (University of Cambridge) · doi:10.17863/cam.39120
Proteomics-based drug discovery and chemoproteomics
Colzani, M., & Carini, M. (2014) · doi:10.4155/ebo.13.350
Hydroxamic Acid-Containing Peptides in the Study of Histone Deacetylases
Moreno–Yruela, C., & Olsen, C. A. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_69
Histone deacetylase inhibitors butyrate and bufexamac inhibit de novo HIV-1 infection in CD4 T-cellsPreprint
Chen, L., Zutz, A., Philippou‐Massier, J., Liebner, T., Keppler, O. T., Choudhary, C., Blum, H., & Schölz, C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.29.067884
A New Drug Discovery Approach Based on Thermal Proteome Profiling to Develop More Effective Drugs
Gholizadeh, E., Rezaei–Tavirani, M., Emadi, A., Karbalaei, R., & Khaleghian, A. (2021) · Middle East Journal of Rehabilitation and Health Studies · doi:10.5812/mejrh.113533
Recent Advances in Small Molecule Target Identification Methods
Beckwith, R. E. J., & Jain, R. K. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00019-3
The MLL3/4 complexes and MiDAC act antagonistically as genome-wide regulators of H4K20ac to control a specific gene expression programPreprint
Wang, X., Rosikiewicz, W., Sedkov, Y., Mondal, B., Kallappagoudar, S., Tvardovskiy, A., Bajpai, R., Xu, B., Pruett‐Miller, S. M., Schneider, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.17.473155
Genetic and functional analysis of rat mammary cancer susceptibility.
Duderstadt, E. L. (2021) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3628
Epigenetic Contributions to Human Cancer
Baylin, S. B. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm006.pub2
Inhibition of lysine-specific demethylase 1 enzyme activity by TAK-418 as a novel therapy for autism
Matsuda, S., & Kimura, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824421-0.00017-5
Supplementary References from Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies
Lee, H.-S., Lee, N., Kouprina, N., Kim, J.-H., Kagansky, A., Bates, S. E., Trepel, J. B., Pommier, Y. G., Sackett, D. L., & Larionov, V. (2023) · doi:10.1158/0008-5472.22408425
Data from A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Jing, T., Wu, J., Deng, H., Lin, X., Peng, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530657
Supplementary References from Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies
Lee, H.-S., Lee, N., Kouprina, N., Kim, J.-H., Kagansky, A., Bates, S. E., Trepel, J. B., Pommier, Y. G., Sackett, D. L., & Larionov, V. (2023) · doi:10.1158/0008-5472.22408425.v1
Epigenetic regulation: Histone modifying enzymes as targets for novel therapeutics
Dietrich, N., & Archer, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00067-8
Mitotic deacetylase complex (MiDAC) recognizes the HIV-1 core promoter to control Tat-activated transcription and latencyPreprint
Wilhelm, E., Poirier, M., Bédard, M., McDonald, P. P., Lavigne, P., Hunter, C. L., & Bell, B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.14.567009
IMAGE-GUIDED SYNTHESIS REVEALS POTENT BLOOD-BRAIN BARRIER PERMEABLE HISTONE DEACETYLASE INHIBITORS
GANTALA, K., & SREENANCHA, G. (2019) · Türk bilgisayar ve matematik eğitimi dergisi · doi:10.61841/turcomat.v10i3.14496
Additional file 4 of Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets
Qiu, H., Su, N., Wang, J., Yan, S., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22619659
Additional file 3 of Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets
Qiu, H., Su, N., Wang, J., Yan, S., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22619656
Additional file 2 of Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets
Qiu, H., Su, N., Wang, J., Yan, S., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22619653
Additional file 1 of Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets
Qiu, H., Su, N., Wang, J., Yan, S., & Li, J. (2023) · Figshare · doi:10.6084/m9.figshare.22619650
Development of improved drug-target profiling methods using mass spectrometry-based thermal stability assays
Phaneuf, C. G. (2023) · doi:10.17760/d20621548
Emerging Technologies for Epigenetic Drug Discovery
(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part2
Mass Spectrometry and Chemical Biology Approaches for Deconvoluting Epigenetic Targets
Burton, A. J., Hamza, G. M., Iannetta, A. A., Miele, E., & Zhang, A. X. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00050
A small molecule increases mycobacterial translation fidelity without a fitness cost by targeting ribosomal protein S5
Wu, J., Chaudhuri, S., Feid, S. C., Joshi, H., Pan, M., Kawaji, Q., Liu, G., & Javid, B. (2026) · mBio · doi:10.1128/mbio.02056-26
Chemoproteomics Sheds Light on Epigenetic Targets of [11C]Martinostat in the Human Brain
Catanese, M. C., Klingl, Y. E., Gilbert, T. M., Strebl, M. G., Hartigan, C. R., Schenone, M., & Hooker, J. M. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00781
TargetSeeker-MS: A Bayesian Inference Approach for Drug–Target Discovery Using Protein Fractionation Coupled to Mass Spectrometry
Lavallée‐Adam, M., Pelletier, A. R., Diedrich, J. K., Pinto, A. F. M., Martínez‐Bartolomé, S., Petrascheck, M., Moresco, J. J., & Yates, J. R. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00269
Interrupting ELMSAN1 repression of nuclear acetyl-CoA production therapeutically reprograms cancer cellsPreprint
Zhao, T., He, L., Wong, L. P., Mei, S., Xia, J., Xu, Y., Vranken, J. G. V., Mazzola, M. C., Chen, L., Rhee, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.25.650293
Knockout of SIN3B modulates transcriptional programs and cell survival in cutaneous melanoma
Matsuyama, L. S. A. S., Harle, V. J., Offord, V., Droop, A., Rabbie, R., Garg, M., Vázquez‐Cruz, M. E., Robles‐Espinoza, C. D., Turner, G., Fraser, D., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107785
Interaktomanalyse einer Lysindeacetylase‐Sondenbibliothek deckt Wechselwirkung zwischen HDAC6 und dem NF‐κB‐Signalweg auf
Seidel, J., Schönfeld, C., Sindlinger, J., Eirich, J., Kirchgäßner, S., Kreienkamp, N., Schulze‐Osthoff, K., Finkemeier, I., Hailfinger, S., & Schwarzer, D. (2025) · Angewandte Chemie · doi:10.1002/ange.202510967
Rapid degradation of 6 class I HDAC complexes reveals minimal functional overlap between complexesPreprint
Turnbull, R. E., Gonchar, O., English, D. M., Wright, T. A., Baker, I. M., Sirvydis, K., Cowley, S. M., & Schwabe, J. W. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671480
Zinc-Dependent Histone Deacetylase (HDAC) Inhibitors: Therapeutic Potential, Pharmacophore Structure, and Methods for Testing Deacylase Activity
Zemskaya, A. S., Kochetkov, S. N., & Kozlov, M. V. (2025) · Molecular Biology · doi:10.1134/s002689332570027x
The role of Bufexamac in reducing anxiety levels: focus on HPA axis dysfunction and neurotransmitter regulation in a rat model of Alzheimer’s disease
Mirehei, M., Motamedi, F., Maghsoudi, N., Khodagholi, F., & Abbaszadeh, F. (2025) · Economy of Tajikistan · doi:10.61882/phypha.29.3.260
A de novo missense variant in MIDEAS results in increased deacetylase activity of the MiDAC HDAC complex causing a neurodevelopmental syndrome
Fairall, L., Sirvydis, K., Turnbull, R. E., Knottnerus, S. J. G., Gonchar, O., Muskett, F. W., Jukes‐Jones, R., van Brussel, L., van de Geer, E., van Gassen, K. L. I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65472-x
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
Xiu, R., Ma, Y., Gao, Y., Chen, Y., Li, X., Wu, Y., Sun, M., Li, Q., Zhao, Y., Xu, S., et al. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70603
De Mycobacterium tuberculosis à la protéomique chimique : utilisation et greffage d'inhibiteurs de lipases et carboxylestérases
Delorme, V. (2012) · theses.fr (ABES) · doi:10.70675/d84ee615z6d6fz4f2fz965ez145ae45b414c
Etude des modifications épigénétiques en fonction de l'agressivité du cancer de la prostate.
Ngollo, M. (2015) · doi:10.70675/768fbc61z4d3fz4645zac49z60bc498f7cc1
Conséquences cliniques et moléculaires de la marque H3K27 me3 HIST1 dans les leucémies aigües myéloïdes sans anomalies cytogénétiques
Garciaz, S. (2018) · theses.fr (ABES) · doi:10.70675/f6bba160z544fz48b5zbb51zb5982923ed7a
Caractérisation de protéines nucléaires ciblées par la bactérie pathogène Listeria monocytogenes
Pourpre, R. (2019) · theses.fr (ABES) · doi:10.70675/3e0b933ez114cz48e2zae8dzabf6fa8d37b1
Caractérisation d'un facteur épigénétique impliqué dans la régulation des cellules souches embryonnaires murines
Benaissa, M. (2018) · theses.fr (ABES) · doi:10.70675/19229be6zcf7cz4317z80f0ze5bd9b22c989
Biochemical, biophysical and structural study of proteins associated to human diseases : tcDAC2 and ADAT complex
Ramos‐Morales, E. (2021) · theses.fr (ABES) · doi:10.70675/c6b28473zf6b6z4024z99bfz05629f0484d7
Développement de nouvelles stratégies thérapeutiques dans les cancers de l’ovaire : intérêt de l’inhibiteur d’HDAC belinostat, seul ou associé avec des molécules BH3-mimétiques, et recherche de stratégies ciblées mimant les mécanismes moléculaires médiateurs de son efficacité
Thomine, C. (2023) · theses.fr (ABES) · doi:10.70675/d1e538f7z6e75z441az8e0fza6253fc7ebf8
Histone acetylation and methylation in rare diseases: from molecular mechanisms to clinical presentations
Akman, B., Gürsoy, S., Gençpınar, P., Polat, A., Hız, A. S., Oktay, Y., Barakat, T. S., Özbek, U., & Erkek, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1777625
ENO1 couples HDAC1 to regulate histone lactylation and gene transcription
Zhai, G., Zhao, F., Wang, Y., Jiang, Z., Li, Y., Fan, Z., Zheng, W., Han, Y., Zhang, J., Zang, Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535245123
The lactate–lactylation axis in tumor radioresistance: metabolic, epigenetic, and immune mechanisms with emerging links to RNA regulation
Zhang, Y., Zhang, J., & Cao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1886398
Histone deacetylases in neurodegeneration and neuronal plasticity
Mehta, B., Nambiar, S., Shirke, O., Pandita, S., & Markandeya, Y. S. (2026) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2026.06.025
Investigation of the classical histone deacetylases and sirtuins using peptide technologies
Rogers, J. M., & Olsen, C. A. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.08.009
BindingDB Entry 6981: Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
BindingDB (2016) · UC San Diego · doi:10.7270/q2tx3d48
BindingDB Entry 50008716: Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
BindingDB (2021) · UC San Diego · doi:10.7270/q26h4mtc
BindingDB Entry 50047097: Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
BindingDB (2017) · UC San Diego · doi:10.7270/q2pk0j09
BindingDB Entry 50045985: Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
BindingDB (2016) · UC San Diego · doi:10.7270/q2hh6mtx
BindingDB Entry 50008782: Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling.
BindingDB (2021) · UC San Diego · doi:10.7270/q2t43xg1
BindingDB Entry 50040972: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
BindingDB (2013) · UC San Diego · doi:10.7270/q25t3mnj
BindingDB Entry 50044723: Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q29c700v
BindingDB Entry 50044721: ST7612AA1, a thioacetate-¿(¿-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q2jw8ggn
BindingDB Entry 50022590: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
BindingDB (2025) · UC San Diego · doi:10.7270/q2pv6r35
BindingDB Entry 50046184: Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q2fn17z1
BindingDB Entry 50016472: Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
BindingDB (2023) · UC San Diego · doi:10.7270/q2xg9w57
BindingDB Entry 50044838: Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles.
BindingDB (2016) · UC San Diego · doi:10.7270/q2fj2jcg
BindingDB Entry 50049298: Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.
BindingDB (2019) · UC San Diego · doi:10.7270/q2x350rs
BindingDB Entry 50000462: Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.
BindingDB (2019) · UC San Diego · doi:10.7270/q2rr21p5
BindingDB Entry 50021367: Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8.
BindingDB (2025) · UC San Diego · doi:10.7270/q2q81jq9
BindingDB Entry 50045763: Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
BindingDB (2016) · UC San Diego · doi:10.7270/q269759b
BindingDB Entry 50009646: Development of Chemical Entities Endowed with Potent Fast-Killing Properties against
BindingDB (2021) · UC San Diego · doi:10.7270/q2x63rdp
BindingDB Entry 50042570: Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
BindingDB (2013) · UC San Diego · doi:10.7270/q2z60qc0
BindingDB Entry 50022578: A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
BindingDB (2025) · UC San Diego · doi:10.7270/q27w6hxb
BindingDB Entry 50043349: Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
BindingDB (2014) · UC San Diego · doi:10.7270/q29g5p7j
BindingDB Entry 50009975: Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
BindingDB (2021) · UC San Diego · doi:10.7270/q29c71wx
BindingDB Entry 50000311: Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
BindingDB (2019) · UC San Diego · doi:10.7270/q2c53p79
BindingDB Entry 50011113: Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
BindingDB (2021) · UC San Diego · doi:10.7270/q2pr80k2
BindingDB Entry 50000517: Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
BindingDB (2019) · UC San Diego · doi:10.7270/q2g44sqs
BindingDB Entry 7446: New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
BindingDB (2016) · UC San Diego · doi:10.7270/q2rr1x2g
Class I Lysine Deacetylases Facilitate Glucocorticoid Receptor-Mediated Transcriptional Activation
Kadiyala, V. (2013) · UA Campus Repository (The University of Arizona)

Authors: Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., Boesche, M., Delling, M., Dümpelfeld, B., Eberhard, D., Huthmacher, C., Mathieson, T., Poeckel, D., Reader, V., Strunk, K., Sweetman, G., Kruse, U., Neubauer, G., Ramsden, N. G., & Drewes, G.
Corresponding author: Bantscheff, Marcus
Drewes, Gerard
ORCID: Bantscheff, Marcus
Hopf, Carsten
Savitski, Mikhail M
Dittmann, Antje
Grandi, Paola
Schlegl, Judith
Abraham, Yann
Becher, Isabelle
Bergamini, Giovanna
Eberhard, Dirk
Mathieson, Toby
Reader, Valérie
Sweetman, Gavain
Neubauer, Gitte
Ramsden, Nigel G
Drewes, Gerard
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2011-01-23
Volume: 29
Issue: 3
Pages: 255-265
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.1759
OpenAlex: W2007139310
Cited by: 659
References: 50
Citations by year: 2026: 15 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 40 · 2021: 37 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 46 · 2016: 69 · 2015: 68 · 2014: 54 · 2013: 58 · 2012: 49
FWCI: 24.95
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
Keywords: histone deacetylase inhibitors, chemoproteomics, hydroxamate inhibitors, bufexamac, HDAC6, HDAC10, drug selectivity, affinity capture
MeSH terms: Histone Deacetylases, Peptide Mapping, Mass Spectrometry, Protein Interaction Mapping, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks